Clinical trial
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients…
NCT00085423 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00085423 |
|---|---|
| Title | Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma |
| Official title | High Dose Interleukin-2 (IL-2) Therapy In "Lymphodepleted Primed" Patients With Metastatic Melanoma |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | aldesleukin, sargramostim, cyclophosphamide, fludarabine phosphate |
| Enrollment | 20 |
| Start date | Feb 1, 2004 |
| Primary completion | Dec 1, 2008 |
| Completion | Feb 1, 2010 |
| First posted | Jun 11, 2004 |
| Last update posted | Apr 10, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: